Interv Akut Kardiol. 2020;19(1):63-66 | DOI: 10.36290/kar.2020.020

Cangrelor (KENGREXAL®): a new old acquintance

Ivo Varvařovský
Kardiologické centrum Agel, Pardubice

Cangrelor is the only intravenous platelet P2Y12 receptor inhibitor with proven clinical efficacy for the reduction of PCI - related ischemic complications. Cangrelor pharmacology, clinical studies, and off-label indications are disscused in this review article.

Keywords: cangrelor, stent thrombosis, PCI.

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Varvařovský I. Cangrelor (KENGREXAL®): a new old acquintance. Interv Akut Kardiol. 2020;19(1):63-66. doi: 10.36290/kar.2020.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angiolillo DJ. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation 2017; 136: 1955-1975. Go to original source...
    2. Harrington RA, Stone GW, McNult S. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329. Go to original source...
    3. Bhatt DL, Lincoff MA, Gibson MC. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330-2341. Go to original source...
    4. Bhatt DL, Stone GW, Mahaffey KW. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368: 1303-1313. Go to original source...
    5. Steg PG, Bhatt DL, Hamm CW. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013; 382: 1981-1992. Go to original source...
    6. Angiolillo DJ, Firstenberg MS, Price MJ. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-274. Go to original source... Go to PubMed...
    7. Franchi F, Rollini F, Rivas A. Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2019; 139: 1661-1670. Go to original source...
    8. Vaduganathan M, Harrington RA, Stone GW. Cangrelor with and without glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol 2017; 69: 176-185. Go to original source...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.